Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Significant decrease in Faecalibacterium among gut microbiota in nonalcoholic fatty liver disease: a large BMI- and sex-matched population study.

Iino C, Endo T, Mikami K, Hasegawa T, Kimura M, Sawada N, Nakaji S, Fukuda S.

Hepatol Int. 2019 Nov;13(6):748-756. doi: 10.1007/s12072-019-09987-8. Epub 2019 Sep 12.

PMID:
31515740
2.

Gut Microbiota and Risk of Persistent Nonalcoholic Fatty Liver Diseases.

Kim HN, Joo EJ, Cheong HS, Kim Y, Kim HL, Shin H, Chang Y, Ryu S.

J Clin Med. 2019 Jul 24;8(8). pii: E1089. doi: 10.3390/jcm8081089.

3.

[Correlation analysis of gut microbiota and biochemical indexes in patients with non-alcoholic fatty liver disease].

Ren SM, Mei L, Huang H, Cao SF, Zhao RH, Zheng PY.

Zhonghua Gan Zang Bing Za Zhi. 2019 May 20;27(5):369-375. doi: 10.3760/cma.j.issn.1007-3418.2019.05.009. Chinese.

PMID:
31177662
4.

Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease.

Miura K, Ohnishi H.

World J Gastroenterol. 2014 Jun 21;20(23):7381-91. doi: 10.3748/wjg.v20.i23.7381. Review.

5.

Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease.

Shen F, Zheng RD, Sun XQ, Ding WJ, Wang XY, Fan JG.

Hepatobiliary Pancreat Dis Int. 2017 Aug 15;16(4):375-381. doi: 10.1016/S1499-3872(17)60019-5.

PMID:
28823367
6.

Fecal and blood microbiota profiles and presence of nonalcoholic fatty liver disease in obese versus lean subjects.

Yun Y, Kim HN, Lee EJ, Ryu S, Chang Y, Shin H, Kim HL, Kim TH, Yoo K, Kim HY.

PLoS One. 2019 Mar 14;14(3):e0213692. doi: 10.1371/journal.pone.0213692. eCollection 2019.

7.

The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota.

Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F, Guy CD, Seed PC, Rawls JF, David LA, Hunault G, Oberti F, Calès P, Diehl AM.

Hepatology. 2016 Mar;63(3):764-75. doi: 10.1002/hep.28356. Epub 2016 Jan 13.

8.

Changes of intestinal bacterial microbiota in coronary heart disease complicated with nonalcoholic fatty liver disease.

Zhang Y, Xu J, Wang X, Ren X, Liu Y.

BMC Genomics. 2019 Nov 14;20(1):862. doi: 10.1186/s12864-019-6251-7.

9.

Modulation of the Gut Microbiota in Rats by Hugan Qingzhi Tablets during the Treatment of High-Fat-Diet-Induced Nonalcoholic Fatty Liver Disease.

Tang W, Yao X, Xia F, Yang M, Chen Z, Zhou B, Liu Q.

Oxid Med Cell Longev. 2018 Dec 23;2018:7261619. doi: 10.1155/2018/7261619. eCollection 2018.

10.

Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease.

Raman M, Ahmed I, Gillevet PM, Probert CS, Ratcliffe NM, Smith S, Greenwood R, Sikaroodi M, Lam V, Crotty P, Bailey J, Myers RP, Rioux KP.

Clin Gastroenterol Hepatol. 2013 Jul;11(7):868-75.e1-3. doi: 10.1016/j.cgh.2013.02.015. Epub 2013 Feb 27.

PMID:
23454028
11.

Microbiome Signatures Associated With Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease.

Schwimmer JB, Johnson JS, Angeles JE, Behling C, Belt PH, Borecki I, Bross C, Durelle J, Goyal NP, Hamilton G, Holtz ML, Lavine JE, Mitreva M, Newton KP, Pan A, Simpson PM, Sirlin CB, Sodergren E, Tyagi R, Yates KP, Weinstock GM, Salzman NH.

Gastroenterology. 2019 Oct;157(4):1109-1122. doi: 10.1053/j.gastro.2019.06.028. Epub 2019 Jun 27.

PMID:
31255652
12.

Diammonium Glycyrrhizinate Protects against Nonalcoholic Fatty Liver Disease in Mice through Modulation of Gut Microbiota and Restoration of Intestinal Barrier.

Li Y, Liu T, Yan C, Xie R, Guo Z, Wang S, Zhang Y, Li Z, Wang B, Cao H.

Mol Pharm. 2018 Sep 4;15(9):3860-3870. doi: 10.1021/acs.molpharmaceut.8b00347. Epub 2018 Aug 2.

PMID:
30036479
13.

Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance.

Da Silva HE, Teterina A, Comelli EM, Taibi A, Arendt BM, Fischer SE, Lou W, Allard JP.

Sci Rep. 2018 Jan 23;8(1):1466. doi: 10.1038/s41598-018-19753-9.

14.

Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far?

Fukui H.

Diseases. 2019 Nov 12;7(4). pii: E58. doi: 10.3390/diseases7040058. Review.

15.

Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach.

Del Chierico F, Nobili V, Vernocchi P, Russo A, De Stefanis C, Gnani D, Furlanello C, Zandonà A, Paci P, Capuani G, Dallapiccola B, Miccheli A, Alisi A, Putignani L.

Hepatology. 2017 Feb;65(2):451-464. doi: 10.1002/hep.28572. Epub 2016 Jun 2.

PMID:
27028797
16.

Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease.

Jiang W, Wu N, Wang X, Chi Y, Zhang Y, Qiu X, Hu Y, Li J, Liu Y.

Sci Rep. 2015 Feb 3;5:8096. doi: 10.1038/srep08096.

17.

An altered fecal microbiota profile in patients with non-alcoholic fatty liver disease (NAFLD) associated with obesity.

Nistal E, Sáenz de Miera LE, Ballesteros Pomar M, Sánchez-Campos S, García-Mediavilla MV, Álvarez-Cuenllas B, Linares P, Olcoz JL, Arias-Loste MT, García-Lobo JM, Crespo J, González-Gallego J, Jorquera Plaza F.

Rev Esp Enferm Dig. 2019 Apr;111(4):275-282. doi: 10.17235/reed.2019.6068/2018.

18.

Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.

Porras D, Nistal E, Martínez-Flórez S, Pisonero-Vaquero S, Olcoz JL, Jover R, González-Gallego J, García-Mediavilla MV, Sánchez-Campos S.

Free Radic Biol Med. 2017 Jan;102:188-202. doi: 10.1016/j.freeradbiomed.2016.11.037. Epub 2016 Nov 25.

PMID:
27890642
19.

Changes of gut microbiota during silybin mediated treatment of high-fat diet-induced nonalcoholic fatty liver diseasein mouse.

Li X, Wang Y, Xing Y, Xing R, Liu Y, Xu Y.

Hepatol Res. 2019 Oct 29. doi: 10.1111/hepr.13444. [Epub ahead of print] Review.

PMID:
31661720
20.

Functional Interactions between Gut Microbiota Transplantation, Quercetin, and High-Fat Diet Determine Non-Alcoholic Fatty Liver Disease Development in Germ-Free Mice.

Porras D, Nistal E, Martínez-Flórez S, Olcoz JL, Jover R, Jorquera F, González-Gallego J, García-Mediavilla MV, Sánchez-Campos S.

Mol Nutr Food Res. 2019 Apr;63(8):e1800930. doi: 10.1002/mnfr.201800930. Epub 2019 Feb 4.

PMID:
30680920

Supplemental Content

Support Center